70920 Federal Register / Vol. 65, No. 229 / Tuesday, November 28, 2000 / Notices

TABLE 1.—Continued

FAP No.1 and Docket

No.

FNC

No.2

FR Citation and

Date Company Section/Part Additive Use

1B4256,

91F–0169

69 56 FR 32435,

July 16, 1991

W. R. Grace,

Ltd.

175.300 Styrene-butadiene-methacrylic

acid terpolymer, 1,2-

benzisothiazolin-3-one, and

sulfosuccinic acid 4-ester with

polyethylene glycol dodecyl

ether, disodium salt.

Components in can

end cements in

contact with

food.

3B4373,

93F–0157

70 58 FR 29231,

May 19, 1993

Shell Oil Co. Proposed new

section.

Two carbon monoxide-olefin

polymers, carbon monoxideethylene, and carbon monoxide-ethylene-propylene.

As articles or components of articles intended for

use in contact

with food.

9A4640,

99F–0052

74 64 FR 3703,

Jan. 25, 1999

Bayer Corp., c/o

ENVIRON

Corp.

173.25 Completely hydrolyzed

tetrapolymer of divinyl benzene, ethyl vinyl benzene, acrylonitrile, and 1, 7-octadiene.

In treating aqueous

sugar solutions

and beverage

water.

9B4672,

99F–2245

83 64 FR 37984,

July 14, 1999

BP Amoco

Chemicals,

Inc.

Proposed new

section in part

177.

Poly(oxy[1,1′-biphenyl]-4,4′-

diyloxy-1,4-

phenylenesulfonyl-1,4-phenylene) prepared by reaction

of biphenol and 4,4′-

dichlorodiphenylsulfone.

As articles or components of articles intended for

contact with

food.

1Food additive petition number.

2 Food contact notification number.

October 25, 2000.

Alan M. Rulis,

Director, Office of Premarket Approval,

Center for Food Safety and Applied Nutrition.

[FR Doc. 00–30326 Filed 11–27–00; 8:45 am]

BILLING CODE: 3510–22–S

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–1620]

2001 National Antimicrobial Resistance

Monitoring System (NARMS) Scientific

Meeting; Public Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice of public meeting.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

following meeting entitled ‘‘2001

NARMS Scientific Meeting.’’ The topic

to be discussed is the results from

NARMS and related antimicrobial

resistance research.

DATES: The public meeting and poster

session will be held on March 15 and

16, 2001, from 8:30 a.m. to 5 p.m. An

early evening poster session and social

hour will be held on March 15, 2001,

from 5:30 p.m. to 7:30 p.m. Submit

written comments by January 29, 2001.

ADDRESSES: The public meeting will be

held at the DoubleTree Hotel, 1750

Rockville Pike, Rockville, MD. Submit

written comments to the Dockets

Management Branch (HFA–305), Food

and Drug Administration, 5630 Fishers

Lane, rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

Kathy S. Hemming, Center for

Veterinary Medicine (HFV–250), Food

and Drug Administration, 7500 Standish

Pl., Rockville, MD 20855, 301–827–

0184, 301–827–7625.

For information about the poster

session contact: Charlotte A. Spires,

Center for Veterinary Medicine (HFV–

250), Food and Drug Administration,

7500 Standish Pl., Rockville, MD 20855,

301–827–6853, e-mail:

cspires@cvm.fda.gov.

Registration: Registration is required.

There is no registration fee for the

meeting. Limited space is available, and

early registration is encouraged.

Logistics for the meeting and the

registration form are available on the

Internet at http://www.fda.gov/cvm/fda/

mappgs/registration.html. Please send

the registration form to Kathy Hemming

(address above). Additional information

about the meeting and the agenda will

be available on the Internet (Internet site

above) before the meeting. If you need

special accommodations due to a

disability, please contact the

DoubleTree Hotel at least 7 days in

advance, 800–222–8733.

Poster abstracts: Abstract preparation

and submission information are

available on the Internet at http://

www.fda.gov/cvm/fda/mappgs/

registration.html. Instructions and

submission forms may be downloaded

in MSWord or WordPerfect. Please send

submission of poster abstract to

Charlotte Spires (address above) by

January 15, 2001.

SUPPLEMENTARY INFORMATION:

I. Background

The National Antimicrobial

Resistance Monitoring System (NARMS)

was established in 1996 as a

collaborative effort among FDA, U.S.

Department of Agriculture (USDA), and

the Centers for Disease Control and

Prevention (CDC). The NARMS was

established in response to

recommendations of several groups,

including a 1995 task force of the

American Society of Microbiology, to

establish a national system in the

United States to monitor levels of

antimicrobial resistance in both animals

and humans. The NARMS program

prospectively monitors changes in

susceptibilities of human and animal

enteric bacteria to 17 antimicrobial

drugs. Bacterial isolates are collected

from human and animal clinical

specimens, from healthy farm animals,

and raw product from food animals. The

objectives of the system include: (1) To

provide descriptive data on the extent

and temporal trends of antimicrobial

susceptibility in Salmonella and other

enteric organisms from human and

animal populations, (2) to facilitate the

identification of resistance in humans

and animals as it arises, and (3) to

provide timely information to

veterinarians and physicians. The

ultimate goal of these activities is to

prolong the lifespan of approved drugs

by promoting prudent and judicious use

Federal Register / Vol. 65, No. 229 / Tuesday, November 28, 2000 / Notices 70921

of antimicrobical drugs and to identify

areas for more detailed investigation.

The NARMS program is designed as

two nearly identical parts: an animal

arm and a human arm. Animal-origin

enteric isolate susceptibility testing is

conducted at the USDA, Agricultural

Research Service’s (ARS) Russell

Research Center in Athens, Georgia.

Sources of nationwide animal-origin

isolates are: (1) Raw product collected

from federally inspected slaughter and

processing plants, (2) clinical specimens

from the National Veterinary Sevices

Laboratory and Veterinary Diagnostic

Laboratory Sentinel Sites, (3) healthy

farm-animal isolates from USDA

National Animal Health Monitoring

System (NAHMS) studies, and (4) onfarm studies conducted by ARS.

Human-origin isolates are submitted by

17 State and local Departments of

Health for testing that is conducted at

the National Center for Infectious

Disease, CDC, in Atlanta, Georgia. The

participating human sites currently

include: California (CA); Colorado;

Connecticut; Florida; Georgia; Kansas;

Los Angeles, CA; Maryland; Minnesota;

Massachusetts; New Jersey; New York

City; New York State; Oregon;

Tennessee; Washington; and West

Virginia. Animal and human isolates

currently monitored in NARMS are nontyphoid Salmonella, Campylobacter,

Escherichia coli, and Enterococci.

Human isolates also include Salmonella

typhi and Shigella. Listeria andVibrio

will be added to the list of human

isolates in 2001.

The CDC/NCID and USDA/ARS

provide the NARMS results annually in

comprehensive summary reports. These

reports are available on the CDC and

FDA/CVM web sites. Additionally

periodic public meetings are held to

present NARMS results and provide a

forum for presentation of other related

antimicrobial resistance research.

II. Submission of Comments

Interested persons may submit to the

Dockets Management Branch (address

above) written comments regarding this

meeting by January 29, 2001. Two

copies of any comments are to be

submitted, except that individuals may

submit one copy, or by fax to 301–827–

6870. Comments are to be identified

with the docket number found in the

brackets in the heading of this

document. Received comments may be

seen in the Dockets Management Branch

between 9 a.m. and 4 p.m., Monday

through Friday.

Dated: November 17, 2000.

Margaret M. Dotzel,

Associate Commissioner for Policy.

[FR Doc. 00–30155 Filed 11–27–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Food Safety Risk Analysis

Clearinghouse; Data Quality

Objectives; Public Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice of public meeting.

SUMMARY: The Food and Drug

Administration (FDA) is announcing a

public meeting cosponsored by the

interagency Risk Assessment

Consortium (RAC) and the Joint

Institute for Food Safety and Applied

Nutrition (JIFSAN). The purpose of this

public meeting is to encourage

discussion and gain input from the

public and professionals on data quality

issues as they relate to the Food Safety

Risk Analysis Clearinghouse

(Clearinghouse).

Date and Time: The public meeting

will be held on December 5, 2000, 6:30

p.m. to 8:30 p.m.

Location: The public meeting will be

held at the Marriott Crystal Gateway

Hotel, Grand Ballroom Salons F and G,

1700 Jefferson Davis Hwy., Arlington,

VA 22202.

Contact: Wesley R. Long, Center for

Food Safety and Applied Nutrition

(HFS–6), Food and Drug

Administration, 200 C St. SW.,

Washington, DC 20204, 202–205–4024,

FAX 301–935–0149, or email:

wlong@cfsan.fda.gov.

Registration: None required.

SUPPLEMENTARY INFORMATION: Risk

assessment generally characterizes the

nature and magnitude of the risks

associated with hazards to human

health. A risk assessment provides an

opportunity to organize scientific

information and helps to clarify the

necessary assumptions and degree of

scientific certainty of the data used in

the risk assessment. Risk assessments

require specific information on the

hazard and on the exposed populations

to provide meaningful information to

public health officials; a risk assessment

may be considered in the development

of risk-management decisions. Although

data quality objectives have been

developed for assessments of chemical

risk, quality objectives for data

addressing foodborne microbial

pathogens are far less developed.

RAC, which includes members from

Federal agencies that have

responsibilities for food safety risk

analysis, was established under the

President’s Food Safety Initiative to

advance the science of food safety risk

assessment and to assist agencies in

fulfilling their specific food safety

regulatory mandates. The RAC also

advises the Clearinghouse, an Internet

based resource of food safety risk data

and risk assessments.

The Clearinghouse has been

developed by JIFSAN, which is a major

component of the FDA food safety

program’s integration with academic

institutions to create intellectual

partnerships. JIFSAN includes research

and outreach components from the

Center for Food Safety and Applied

Nutrition, the Center for Veterinary

Medicine, the University of Maryland

(UMD), the Virginia-Maryland Regional

College of Veterinary Medicine at UMD,

and others. JIFSAN provides a neutral

environment in which experts from

industry, consumer and trade groups,

international organizations, government,

and academia can pool their resources

and ideas to provide the scientific base

for the development of sound public

health policy.

Consistent with the goals of RAC and

JIFSAN, an open public meeting will be

held on data quality issues. The RAC

and JIFSAN are seeking input to further

the ability of the Clearinghouse to serve

as a reliable data resource for use by

researchers, industry, and international,

Federal and State agencies. The main

topic at this meeting will be data quality

for microbiological and antimicrobial

risk analyses. The draft agenda includes

brief presentations on the RAC and the

Clearinghouse followed by speakers

from the Society of Risk Analysis (SRA)

and international organizations. Public

comment and discussion will follow the

presentations.

This public meeting is being held in

conjunction with the annual SRA

meeting to leverage access by the RAC

to an audience of risk analysis

professionals. The meeting is also open

to the public, and opportunity for public

comment will be provided.

More information about the meeting

site is available on the Internet at http:/

/www.sra.org. The meeting agenda and

summary will be posted at http://

www.foodriskclearinghouse.umd.edu.

The agenda posted on this Internet site

will identify the specific time set aside

for public comment.